Cargando…

ESMO-Magnitude of Clinical Benefit Scale (MCBS) group

Detalles Bibliográficos
Autor principal:	Amaral, Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Podcast
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802955/ https://www.ncbi.nlm.nih.gov/pubmed/31673431 http://dx.doi.org/10.1136/esmoopen-2019-000594

Ejemplares similares

ESMO Leaders Generation Programme: an alumni insight
por: Arruda, Leticia De Mattos, et al.
Publicado: (2018)

ESMO Open: news in breast cancer 2019
por: Lambertini, Matteo
Publicado: (2020)

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017)

ESMO presidential symposium wrap up: the ClarIDHy trial
por: Abou-Alfa, Ghassan K
Publicado: (2020)

ESMO20 YO for YO: highlights on oncogene-addicted NSCLC
por: Lim, K.H.J., et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on upper GI tumours
por: Cardone, C., et al.
Publicado: (2020)

ESMO Open special series on new emerging targets in cancer immunotherapy
por: Lambertini, Matteo
Publicado: (2020)

ESMO20 YO for YO: highlights on metastatic NSCLC-Keynote 024 update
por: Mariamidze, E., et al.
Publicado: (2021)

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
por: Gyawali, B., et al.
Publicado: (2021)

ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer
por: Punie, K., et al.
Publicado: (2020)

PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
por: Kiesewetter, Barbara, et al.
Publicado: (2023)

ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer
por: Schmid, Peter
Publicado: (2018)

ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib
por: Lambertini, M., et al.
Publicado: (2020)

ESMO20 YO for YO: highlights on metastatic renal cell carcinoma—the CheckMate-9ER trial
por: Kfoury, M., et al.
Publicado: (2021)

Report from the ESMO 2018 presidential symposium—Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE
por: Parker, Chris
Publicado: (2018)

ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer
por: Matikas, A., et al.
Publicado: (2020)

EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer
por: Sapir, E., et al.
Publicado: (2023)

Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1
por: Pichler, M., et al.
Publicado: (2021)

Adjuvant and neoadjuvant therapies in melanoma
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2020)

Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores
por: Broekman, K.E., et al.
Publicado: (2021)

How to Conduct a Clinical Trial During a Pandemic—An Interview with Dr. David Boulware
Publicado: (2020)

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life
por: Ciardiello, Fortunato, et al.
Publicado: (2016)

What is new on the horizon in melanoma brain metastasis?
por: Margolin, Kim
Publicado: (2019)

Highlights in breast cancer from ASCO 2016
por: Cardoso, Fatima
Publicado: (2016)

Tumour network in glioma
por: Winkler, Frank
Publicado: (2016)

Highlights from the San Antonio Breast Cancer Symposium 2015
por: Jassem, Jacek
Publicado: (2016)

ASCO highlights podcast: head and neck cancers
por: Merlano, Marco
Publicado: (2016)

Cancer genome: highlights of a Nature Medicine perspective
por: Voest, Emile
Publicado: (2016)

Recent advances in adjuvant therapy for patients with melanoma
por: Weber, Jeffrey
Publicado: (2018)

Immunotherapy in lung cancer
por: Vansteenkiste, Johan F
Publicado: (2018)

New therapeutic targets in the inflammatory microenvironment
por: Tartour, Eric
Publicado: (2018)

Questions asked in the everyday practice: immune checkpoint inhibitors
por: Haanen, John B A G
Publicado: (2018)

Macrophage repolarisation therapy in colorectal cancer
por: Halama, Niels
Publicado: (2018)

Epigenetic biomarkers in cancer
por: Egger, Gerda
Publicado: (2018)

Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer
por: Argiles, Guillem
Publicado: (2018)

Biosimilars in oncology
por: Tabernero, Josep
Publicado: (2018)

Introducing the Metastatic Breast Cancer Project: a novel patient-partnered initiative to accelerate understanding of MBC
por: Parry, Marina
Publicado: (2018)

Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer
por: Vansteenkiste, Johan F
Publicado: (2018)

Tumor evolution in non-small-cell lung cancer
por: Parry, Marina
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8fncu9i66qh3fk4dlv0o9urmrr